Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Quentin, Wilm ^a   Terris Prestholt, Fern ^b   Changalucha, John ^c   Soteli, Selephina ^d   Edmunds, W John ^b   Hutubessy, Raymond ^e   Ross, David A ^b   Kapiga, Saidi ^b,d   Hayes, Richard ^b   Watson Jones, Deborah ^b,d  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^d National Institute for Medical Research   (Tanzania)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Africa; costs and cost analysis; economics papillomavirus vaccines; uterine cervical neoplasms

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CHILD; COST BENEFIT ANALYSIS; CRYOPRESERVATION; FEMALE; HEALTH CARE COST; HUMAN; PRIMARY SCHOOL; SALARY; SCHOOL CHILD; VACCINATION;

ADOLESCENT; CHILD; COSTS AND COST ANALYSIS; FEMALE; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SCHOOLS; TANZANIA; UTERINE CERVICAL NEOPLASMS;

EID: 84868660406     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-137     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006, 24(Suppl 3):3-11.
3. WHO/ICO Human Papillomavirus and Related Cancers. Summary report update for Tanzania 2010, Barcelona, Spain: WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre), WHO/ICO.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers CD, Parkin DM. Globocan 2008 v 1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010, Lyon, France: International Agency for Research on Cancer.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482.
6. Frazer IH. HPV vaccines and the prevention of cervical cancer. Update Cancer Therapeutics 2008, 3:43-48.
7. Bonanni P, Levi M, Latham NB, Bechini A, Tiscione E, Lai P, Panatto D, Gasparini R, Boccalini S. An overview on the implementation of HPV vaccination in Europe. Hum Vaccin 2009, 7:128-135.
8. Tanzania Ministry of Health and Social Welfare Expanded Programme on Immunization 2010 - 2015 Comprehensive Multi Year Plan 2011, Dar es Salaam, Tanzania: The United Republic of Tanzania, Ministry of Health and Social Welfare (MOHSW), Tanzania Ministry of Health and Social Welfare.
9. GAVI HPV Factsheet 2011, Geneva, Switzerland: Global Alliance, GAVI.
10. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim S. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26:4080-4093. 10.1016/j.vaccine.2008.04.053, 18550229.
11. Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, Diaz M, Goldie SJ. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 2012, 130:2672-2684. 10.1002/ijc.26269, 21717458.
12. Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, Sanjose S D, Wight D, Changalucha J, Hayes R. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis 2012, 206:678-686. 10.1093/infdis/jis407, 3414230, 22711908.
13. National Bureau of Statistics (NBS) and ICF Macro Tanzania Demographic and Health Survey 2010 2011, Dar es Salaam, Tanzania: NBS, National Bureau of Statistics (NBS) and ICF Macro.
14. UNICEF Statistics for the United Republic of Tanzania. UNICEF., http://www.unicef.org/infobycountry/tanzania_statistics.html
15. Remes P, Selestine V, Changalucha J, Ross DA, Wight D, de Sanjosé S, Kapiga S, Hayes RJ, Watson-Jones D. A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine 2012, 30:5363-5367. 10.1016/j.vaccine.2012.06.025, 3409375, 22732428.
16. WHO Guidelines for estimating costs of introducing new vaccines into the national immunization system 2002, Geneva, Switzerland: World Health Organisation (WHO), WHO.
17. UNAIDS Costing guidelines for HIV prvention strategies 2000, Geneva, Switzerland: Joint United Nations Program on HIV/AIDS (UNAIDS), UNAIDS.
18. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis 2003, Geneva, Switzerland: World Health Organization (WHO).
19. UICC UICC welcomes commitment to lower prices for HPV vaccines. UICC., http://www.uicc.org/programmes/uicc-welcomes-commitment-lower-prices-hpv-vaccines
20. IMF World Economic Outlook Database. Selected Indicators for Tanzania and the United States 2011, Washington, DC: International Monetary Fund (IMF), IMF.
21. OANDA Historical exchange rates. OANDA., http://www.oanda.com/currency/historical-rates/
22. MOEVT Basic Statistics in Education - Regional 2010 2011, Dar es Salaam, Tanzania: Ministry of Education and Vocational Training (MOEVT), MOEVT.
23. Hutubessy R, Levin A, Wang S, Morgan W, Ally M, Broutet N, John T. Costing nationwide HPV vaccine delivery in Low and Middle Income Countries using the WHO Cervical Cancer Prevention and Control Costing Tool: A case study of The United Republic of Tanzania. BMC Med 2012,
24. WHO Immunization Profile - United Republic of Tanzania 2012, Geneva, Switzerland: World Health Organization (WHO), WHO.
25. BOT Monthly Economic Review June 2010 2010, Dar es Salaam, Tanzania: Bank of Tanzania (BOT), BOT.
26. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994, 3:95-104. 10.1002/hec.4730030206, 8044216.
27. WHO Human papillomavirus vaccines WHO position paper. Wkly Epidemiolog Rec 2009, 84:118-131. WHO.
28. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26:4080-4093. 10.1016/j.vaccine.2008.04.053, 18550229.
29. PATH, Uganda National Expanded Programme on Immunisation (UNEPI), Child Health and Development Centre (CHDC) HPV Vaccine Demonstration Project in Uganda: Results, Lessons Learnt, and Recommendations 2010, Seattle, WA: PATH, PATH, Uganda National Expanded Programme on Immunisation (UNEPI), Child Health and Development Centre (CHDC).
30. Tate JE, Rheingans RD, O'Reilly CE, Obonyo B, Burton DC, Tornheim JA, Adazu K, Jaron P, Ochieng B, Kerin T, Calhoun L, Hamel M, Laserson K, Breiman RF, Feikin DR, Mintz ED, Widdowson M. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. J Infect Dis 2009, 200(Suppl 1):S76-84.
31. Tate JE, Kisakye A, Mugyenyi P, Kizza D, Odiit A, Braka F. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Vaccine 2011, 29:3329-3334. 10.1016/j.vaccine.2010.12.122, 21241733.
32. Berry SA, Johns B, Shih C, Berry AA, Walker DG. The cost-effectiveness of rotavirus vaccination in Malawi. J Infect Dis 2010, 202:S108-15. 10.1086/653578, 20684689.
33. Bratt JH, Foreit J, Chen PL, West C, Janowitz B, Vargas T D. A comparison of four approaches for measuring clinician time use. Health Policy Plan 1999, 14:374-381. 10.1093/heapol/14.4.374, 10787653.
34. Zaba B, Isingo R, Wringe A, Marston M, Slaymaker E, Urassa M. Influence of timing of sexual debut and first marriage on sexual behaviour in later life: findings from four survey rounds in the Kisesa cohort in northern Tanzania. Sex Trans Infect 2009, 85:i20.
35. Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin 2011, 7:161-169. 10.4161/hv.7.2.13690, 21307652.
36. Roteli-Martins C, Naud P, Borba P D, Teixeira J, Carvalho N D, Zahaf T, Sanchez N, Geeraerts B, Descamps D. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012, 8.
37. David M, van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Cervical Cancer Vaccines: The Role of the Immunological Profile and Future Expectations for Vaccination II. Gynecol Oncol 2009, 115:S1. 10.1016/j.ygyno.2009.01.011, 19217149.
38. Griffiths UK, Korczak VS, Ayalew D, Yigzaw A. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia. Vaccine 2009, 27:1426-1432. 10.1016/j.vaccine.2008.12.037, 19146901.
39. Biellik R, Levin C, Mugisha E, LaMontagne DS, Bingham A, Kaipilyawar S, Gandhi S. Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine 2009, 27:6203-6209. 10.1016/j.vaccine.2009.08.003, 19698808.
40. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103:1444-1451. 10.1093/jnci/djr319, 3186781, 21908768.
41. Kim S, Sweet S, Chang J, Goldie SJ. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden. BMC Infect Dis 2011, 11:174. 10.1186/1471-2334-11-174, 3129299, 21679420.